0001654151-22-000015 | 10-Q | XBRL Viewer | Deciphera Pharmaceuticals INC

Print Document View Excel Document

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 30, 2022	Jul. 29, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-38219
Entity Registrant Name	DECIPHERA PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	30-1003521
Entity Address, Address Line One	200 Smith Street
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	209-6400
Title of 12(b) Security	Common Stock, $0.01 Par Value Per Share
Trading Symbol	DCPH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		66,822,086
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001654151
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 109,698	$ 87,063
Short-term marketable securities	274,149	198,571
Accounts receivable, net	25,851	20,595
Inventory	20,889	14,125
Prepaid expenses and other current assets	17,944	18,660
Total current assets	448,531	339,014
Long-term marketable securities	9,208	41,950
Long-term investments—restricted and other long-term assets	3,269	3,110
Property and equipment, net	7,353	8,610
Operating lease assets	38,676	36,800
Total assets	507,037	429,484
Current liabilities:
Accounts payable	16,229	13,130
Accrued expenses and other current liabilities	55,214	80,773
Operating lease liabilities	3,102	2,870
Total current liabilities	74,545	96,773
Operating lease liabilities, net of current portion	27,481	27,991
Total liabilities	102,026	124,764
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.01 par value per share; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.01 par value per share; 125,000,000 shares authorized; 66,815,511 shares and 58,549,644 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	668	585
Additional paid-in capital	1,549,996	1,358,516
Accumulated other comprehensive income (loss)	(1,268)	51
Accumulated deficit	(1,144,385)	(1,054,432)
Total stockholders' equity	405,011	304,720
Total liabilities and stockholders' equity	$ 507,037	$ 429,484

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	66,815,511	58,549,644
Common stock, shares outstanding (in shares)	66,815,511	58,549,644

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Total revenues	$ 32,494	$ 23,573	$ 61,717	$ 48,729
Cost and operating expenses:
Cost of sales	1,799	1,275	2,181	1,497
Research and development	44,858	59,984	92,270	115,665
Selling, general, and administrative	29,625	32,828	57,946	63,575
Total cost and operating expenses	76,282	94,087	152,397	180,737
Loss from operations	(43,788)	(70,514)	(90,680)	(132,008)
Other income (expense):
Interest and other income, net	727	81	727	277
Total other income (expense), net	727	81	727	277
Net loss	$ (43,061)	$ (70,433)	$ (89,953)	$ (131,731)
Net loss per share—diluted (in dollars per share)	$ (0.60)	$ (1.21)	$ (1.31)	$ (2.28)
Net loss per share—basic (in dollars per share)	$ (0.60)	$ (1.21)	$ (1.31)	$ (2.28)
Weighted average common shares outstanding—diluted (in shares)	72,133,428	57,987,095	68,441,998	57,867,795
Weighted average common shares outstanding—basic (in shares)	72,133,428	57,987,095	68,441,998	57,867,795
Comprehensive loss:
Net loss	$ (43,061)	$ (70,433)	$ (89,953)	$ (131,731)
Other comprehensive income (loss):
Unrealized losses on marketable securities	(657)	(53)	(1,197)	(23)
Currency translation adjustment	(48)	36	(122)	38
Total other comprehensive income (loss)	(705)	(17)	(1,319)	15
Total comprehensive loss	(43,766)	(70,450)	(91,272)	(131,716)
Share-based compensation expense	12,988	12,371	27,256	23,490
Product revenues, net
Total revenues	31,497	22,048	60,306	42,010
Collaboration revenues
Total revenues	$ 997	$ 1,525	$ 1,411	$ 6,719

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Warrant
Beginning balance (in shares) at Dec. 31, 2020		57,596,144
Beginning balance at Dec. 31, 2020	$ 543,676	$ 576	$ 1,297,557	$ 11	$ (754,468)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock option and incentive and employee stock purchase plans (in shares)		265,746
Issuance of common stock under stock option and incentive and employee stock purchase plans	2,658	$ 2	2,656
Issuance of common stock sold in public offering, net of underwriting discounts, commissions and offering costs (in shares)		172,094
Issuance of common stock, net of underwriting discounts, commissions and offering costs	8,548	$ 2	8,546
Stock-based compensation expense	23,490		23,490
Other comprehensive income (loss)	15			15
Net loss	(131,731)				(131,731)
Ending balance (in shares) at Jun. 30, 2021		58,033,984
Ending balance at Jun. 30, 2021	446,656	$ 580	1,332,249	26	(886,199)
Beginning balance (in shares) at Mar. 31, 2021		57,901,020
Beginning balance at Mar. 31, 2021	503,013	$ 579	1,318,157	43	(815,766)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock option and incentive and employee stock purchase plans (in shares)		132,964
Issuance of common stock under stock option and incentive and employee stock purchase plans	1,722	$ 1	1,721
Stock-based compensation expense	12,371		12,371
Other comprehensive income (loss)	(17)			(17)
Net loss	(70,433)				(70,433)
Ending balance (in shares) at Jun. 30, 2021		58,033,984
Ending balance at Jun. 30, 2021	446,656	$ 580	1,332,249	26	(886,199)
Beginning balance (in shares) at Dec. 31, 2021		58,549,644
Beginning balance at Dec. 31, 2021	304,720	$ 585	1,358,516	51	(1,054,432)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock option and incentive and employee stock purchase plans (in shares)		447,312
Issuance of common stock under stock option and incentive and employee stock purchase plans	951	$ 5	946
Issuance of common stock sold in public offering, net of underwriting discounts, commissions and offering costs (in shares)		7,501,239				317,316
Issuance of common stock, net of underwriting discounts, commissions and offering costs	163,353	$ 75	163,278			$ 3
Stock-based compensation expense	27,256		27,256
Other comprehensive income (loss)	(1,319)			(1,319)
Net loss	(89,953)				(89,953)
Ending balance (in shares) at Jun. 30, 2022		66,815,511
Ending balance at Jun. 30, 2022	405,011	$ 668	1,549,996	(1,268)	(1,144,385)
Beginning balance (in shares) at Mar. 31, 2022		58,697,263
Beginning balance at Mar. 31, 2022	271,565	$ 586	1,372,866	(563)	(1,101,324)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock option and incentive and employee stock purchase plans (in shares)		299,693
Issuance of common stock under stock option and incentive and employee stock purchase plans	868	$ 4	864
Issuance of common stock sold in public offering, net of underwriting discounts, commissions and offering costs (in shares)		7,501,239				317,316
Issuance of common stock, net of underwriting discounts, commissions and offering costs	163,353	$ 75	163,278			$ 3
Stock-based compensation expense	12,988		12,988
Other comprehensive income (loss)	(705)			(705)
Net loss	(43,061)				(43,061)
Ending balance (in shares) at Jun. 30, 2022		66,815,511
Ending balance at Jun. 30, 2022	$ 405,011	$ 668	$ 1,549,996	$ (1,268)	$ (1,144,385)

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (43,061)	$ (70,433)	$ (89,953)	$ (131,731)	$ (300,000)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Stock-based compensation expense			27,256	23,490
Depreciation expense			1,603	1,475
Noncash lease expense			1,954	1,675
Net amortization (accretion) of premium (discounts) on marketable securities			222	847
Changes in operating assets and liabilities:
Accounts receivable			(5,397)	(4,712)
Inventory			(6,911)	(4,156)
Prepaid expenses and other current assets			(1,992)	(2,489)
Increase (Decrease) in Other Noncurrent Assets			(160)	0
Accounts payable			3,136	1,711
Accrued expenses and other current liabilities			(25,212)	(4,536)
Operating lease liabilities			(1,422)	(1,223)
Net cash flows used in operating activities			(96,876)	(119,649)
Cash flows from investing activities:
Purchases of marketable securities			(181,885)	(212,121)
Maturities of marketable securities			137,630	260,612
Sales of marketable securities			0	16,033
Purchases of property and equipment			(287)	(1,069)
Net cash flows (used in) provided by investing activities			(44,542)	63,455
Cash flows from financing activities:
Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions			163,778	8,588
Proceeds from Warrant Exercises			3	0
Payments of Stock Issuance Costs			(425)	(40)
Proceeds from stock option exercises and employee stock purchase plan			951	2,658
Net cash flows provided by financing activities			164,307	11,206
Net increase (decrease) in cash and cash equivalents			22,889	(44,988)
Effect of exchange rate changes on cash and cash equivalents			(254)	38
Cash and cash equivalents at beginning of period			87,063	135,897	$ 135,897
Cash and cash equivalents at end of period	$ 109,698	$ 90,947	$ 109,698	$ 90,947

Nature of the Business and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of the Business and Summary of Significant Accounting Policies

Nature of the Business

Deciphera Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Leveraging its proprietary switch-control inhibitor platform and deep expertise in kinase biology, the Company designs kinase inhibitors to target the switch pocket region of the kinase with the goal of developing potentially transformative medicines. Through its patient-inspired approach, the Company seeks to develop a broad portfolio of innovative medicines to improve treatment outcomes. QINLOCK, the Company's switch-control kinase inhibitor, was engineered using its proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is approved in Australia, Canada, China, the European Union (EU), Hong Kong, Switzerland, Taiwan, the United States (U.S.), and the United Kingdom (U.K.) for the treatment of fourth-line GIST. The Company wholly owns QINLOCK and all of its drug candidates with the exception of a development and commercialization out-license agreement for QINLOCK in Greater China. In addition to QINLOCK, the Company has identified and advanced multiple drug candidates from its platform into clinical studies, including vimseltinib and DCC-3116.

The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, market acceptance and the successful commercialization of QINLOCK or any of the Company's current or future drug candidates for which it receives marketing approval, protection of proprietary technology, ability to complete late-stage clinical trials, ability to obtain and maintain regulatory approvals, compliance with government regulations, the impact of the novel coronavirus (COVID-19) pandemic on its operations, and the ability to secure additional capital to fund operations. QINLOCK and the Company's drug candidates currently under development will require significant additional research and development efforts, including extensive preclinical and/or clinical testing and regulatory approval. In addition to supporting its research and development efforts, the Company will be required to invest in the Company's commercial capabilities and infrastructure, to support its commercialization of QINLOCK, the Company's first approved drug, and any current or future drug candidate for which the Company obtains marketing approval. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if the Company's drug development and commercialization efforts are successful, it is uncertain when, if ever, the Company will realize sufficient revenue to result in a profit from product sales of QINLOCK or any current or future drug candidates for which it receives marketing approval.

The full extent to which the COVID-19 pandemic, or the future outbreak of any other highly infectious or contagious diseases, may impact the Company's business, including its preclinical studies, clinical trial operations, or commercialization efforts will depend on continuously changing circumstances, which are highly uncertain and cannot be predicted at this time, such as the duration of such pandemic including future waves of infection, new strains of the virus that causes COVID-19, or the impact of effective vaccines, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. The Company is continuing to monitor the long-term impact of COVID-19, if any, on its financial condition and results of operations. The ongoing fluidity of this situation precludes any prediction as to the full impact of the COVID-19 pandemic but it could have a material adverse effect on the Company's business, financial condition, and results of operations. The COVID-19 pandemic may also have the effect of heightening the risks to which the Company is subject, including various aspects of the Company's preclinical studies and ongoing clinical trials, the reliance on third parties in the Company's supply chain for materials and manufacturing of the Company's drug and drug candidates, disruptions in health regulatory agencies' operations globally, the volatility of the Company's common stock, and its ability to access capital markets, and the Company's ability to successfully commercialize and generate revenue from sales of QINLOCK.

In August 2020, the Company entered into an Open Market Sale Agreement℠ (the Sales Agreement) with Jefferies LLC (Jefferies), pursuant to which the Company may issue and sell shares of its common stock having aggregate offering proceeds of up to $200.0 million (the Shares) from time to time through Jefferies as its sales agent. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Company may sell the Shares in amounts and at times to be determined by the Company from time to time subject to the terms and conditions of the Sales Agreement, but it has no obligation to sell any Shares under the Sales Agreement. The Company or Jefferies may suspend or terminate the offering of Shares upon notice to the other party and subject to other conditions. During the six months ended June 30, 2022, the Company did not issue any shares under the Sales Agreement. During the six months

ended June 30, 2021, the Company issued 172,094 shares under the Sales Agreement resulting in net proceeds of $8.5 million after deducting underwriting discounts and commissions and other offering expenses. On April 26, 2022, the Company delivered written notice to Jefferies that it was suspending and terminating the prospectus related to the Company’s common stock (the ATM Prospectus) issuable pursuant to the Sales Agreement. As a result, the Company will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement, or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect.

In April 2022, the Company entered into an underwriting agreement with J.P. Morgan Securities LLC and Jefferies, as representatives of the several underwriters named therein, relating to the issuance and sale of an aggregate of 7,501,239 shares of its common stock at a public offering price of $10.00 per share of common stock to certain investors. In addition, the Company offered pre-funded warrants to purchase 9,748,761 shares of its common stock at a purchase price of $9.99 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.01 exercise price per share of each pre-funded warrant. The offering closed on April 29, 2022, resulting in net proceeds of $163.4 million after deducting underwriting discounts and commissions and other offering expenses.

As the pre-funded warrants are indexed to the Company’s common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the pre-funded warrants as additional paid-in capital on the Company’s consolidated balance sheets.

The pre-funded warrants are exercisable at any time. Certain holders of pre-funded warrants may not exercise the pre-funded warrant if the holder, together with its affiliates, would beneficially own more than 4.99%, 9.99%, or 28.22% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. A holder of pre-funded warrants may increase or decrease this percentage not in excess of 19.99%, with the exception of one holder, by providing at least 61 days’ prior notice to the Company.

During the six months ended June 30, 2022, 317,316 shares of pre-funded warrants were exercised resulting in net proceeds of less than $0.1 million. As of June 30, 2022, there were 9,431,445 pre-funded warrants outstanding.

Basis of Presentation

The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has incurred recurring losses including net losses of $90.0 million and $300.0 million for the six months ended June 30, 2022 and the year ended December 31, 2021, respectively. As of June 30, 2022, the Company had an accumulated deficit of $1.1 billion. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents, and marketable securities of $393.1 million as of June 30, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of these consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to fund its operations.

The Company will need to obtain substantial additional funding in connection with continuing operations. If the Company is unable to raise capital when needed, or on attractive terms, it could be forced to delay, reduce, or eliminate its research or drug development programs or certain commercialization efforts. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.

These consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated.

Unaudited Interim Financial Information

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (GAAP).

The consolidated balance sheet as of December 31, 2021 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited consolidated financial statements as of June 30, 2022 and

for the three and six months ended June 30, 2022 and 2021 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company's audited financial statements and the notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K (Form 10-K) on file with the SEC.

In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company's consolidated financial position as of June 30, 2022 and consolidated results of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021 and consolidated cash flows for the six months ended June 30, 2022 and 2021 have been made. The consolidated results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.

The significant accounting policies used in preparation of these consolidated financial statements for the three and six months ended June 30, 2022 are consistent with those discussed in Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements in the Company's Form 10-K for the year ended December 31, 2021.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, product revenue reserves, the accrual for research and development expenses, and the valuation of stock-based option awards. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

Income Taxes

Effective for tax years beginning on or after January 1, 2022, research and experimental expenditures under Internal Revenue Code Section 174 must be capitalized over five years when performed in the U.S. and 15 years for research and experimental expenditures performed outside of the U.S. The modification is an accounting method change that will require the filing of Form 3115 with the Company's 2022 tax return. As of June 30, 2022, the Company has performed an assessment of the impact of this legislation enactment and determined that it will not result in income tax due to enough net operating losses available that are not subject to an 80% limitation. The Company maintains its full valuation allowance.

Leases - Sublease

All of the Company's leases are operating leases. The Company determines the classification of a sublease at inception. If the sublease is determined to be an operating lease, the Company will recognize sublease income on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. If the sublease is determined to be a sales-type lease or direct financing lease, the Company will derecognize the right-of-use asset from the Company's original lease and record a net investment in the sublease and evaluate for impairment. The Company will account for the lease liability of the original lease based on the accounting for a lease liability in a finance lease.

In May 2022, the Company entered into a sublease agreement to sublease 44,343 square feet of space at 200 Smith Street, Waltham, MA, for a term of three years for $8.9 million over the term of the sublease. The Company determined the sublease to be an operating lease. Therefore the Company will recognize sublease income on a straight-line basis over the lease term in its consolidated statement of operations and comprehensive income. The Company will continue to account for the right-of-use asset and related liability of the original lease as it did prior to the commencement of the sublease. During the three and six months ended June 30, 2022, the Company recognized $0.3 million of sublease income relating to lease payments within selling, general, and administrative expenses in the consolidated statement of operations and comprehensive loss.

Net Loss per Share

Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding for the period, including the pre-funded warrants given their nominal exercise price. Diluted net income (loss) per share is computed by dividing the diluted net income (loss) by the weighted average number of common shares, including the pre-funded warrants and potential dilutive common shares assuming the dilutive effect as determined using the treasury stock method.

For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss for the three and six months ended June 30, 2022 and 2021.

The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:


	As of June 30,
	2022	2021
Options to purchase common stock	8,205,617	6,798,894
Unvested restricted common stock units	1,942,621	814,277
Unvested employee stock purchase plan shares	53,429	34,183
Total	10,201,667	7,647,354

Revenues

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenues

Net Product Revenues

To date, the Company's only source of product revenues has been from the sales of QINLOCK, for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.

Net product revenues by geography consisted of the following:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2022		2021		2022		2021
U.S.	$	23,733	$	20,732	$	47,142	$	40,019
Rest of world	7,764		1,316		13,164		1,991
Total product revenues, net	$	31,497	$	22,048	$	60,306	$	42,010

Activity in each of the product revenue allowance and reserve categories is summarized as follows:


(in thousands)	Trade discounts and allowances		Chargebacks and administrative fees		Government rebates and other incentives		Returns		Total
Balance as of December 31, 2021	$	267	$	494	$	7,863	$	817	$	9,441
Provision related to sales in the current year	1,734		3,686		5,536		1,211		12,167
Adjustments related to prior period sales	—		(16)		(164)		(239)		(419)
Credits and payments made during the period	(1,566)		(3,543)		(2,416)		(1,126)		(8,651)
Balance as of June 30, 2022	$	435	$	621	$	10,819	$	663	$	12,538

The total reserves described above are summarized as components of the Company's consolidated balance sheets as follows:


(in thousands)	As of June 30, 2022		As of December 31, 2021
Reduction of accounts receivable, net	$	996	$	719
Component of accrued expenses and other current liabilities	11,542		8,722
Total revenue-related reserves	$	12,538	$	9,441

Collaboration Revenues

Zai License Agreement

In June 2019, the Company entered into a License Agreement (the Zai License Agreement) with an affiliate of Zai Lab (Shanghai) Co., Ltd. (Zai), pursuant to which the Company granted Zai exclusive rights to develop and commercialize QINLOCK, including certain follow-on compounds (the Licensed Products), in Greater China (the Territory). The Company retains exclusive rights to, among other things, develop, manufacture, and commercialize the Licensed Products outside the Territory.

Pursuant to the terms of the Zai License Agreement, the Company received an upfront cash payment of $20.0 million and three development milestone payments totaling $12.0 million and will be eligible to receive up to $173.0 million in potential development and commercial milestone payments, consisting of up to $38.0 million of development milestones and up to $135.0 million of commercial milestones. In addition, during the term of the Zai License Agreement, Zai will be obligated to pay the Company tiered percentage royalties ranging from low to high teens on annual net sales of the Licensed Products in the Territory, subject to adjustments in specified circumstances. Additionally, certain costs incurred by the Company associated with the Zai License Agreement are reimbursed by Zai.

During the three and six months ended June 30, 2022 and 2021, the Company recognized royalty revenues under the Zai License Agreement, which the Company began recognizing in the second quarter of 2021 following the approval from the China National Medical Products Administration (China NMPA).

During the six months ended June 30, 2021, revenues recognized under the Zai License Agreement included the achievement of a $5.0 million development milestone associated with the approval of QINLOCK for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib, by the China NMPA in March 2021.

Please read Note 3, Revenues, to the consolidated financial statements in the Company's Form 10-K for the year ended December 31, 2021 for further details on the Zai License Agreement.

Zai Supply Agreement

In February 2020, the Company entered into a Supply Agreement (the Zai Supply Agreement) with Zai, as required by terms in the Zai License Agreement, pursuant to which the Company will supply the Licensed Products to Zai for use in the Territory for clinical trials as well as commercial inventory, if QINLOCK obtained regulatory approval in the Territory. In March 2021, QINLOCK was approved in the People's Republic of China (the PRC) and in Hong Kong. In September 2021, QINLOCK was approved in Taiwan. Subject to the Zai Supply Agreement, costs incurred by the Company for clinical and commercial supply are reimbursed by Zai.

During the second quarter of 2021, following the approvals of QINLOCK in the PRC and Hong Kong in March 2021, the Company began recognizing revenues associated with sales of commercial inventory of QINLOCK under the Zai Supply Agreement.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Marketable Securities and Fair Value Measurements

6 Months Ended

Jun. 30, 2022

Investments, All Other Investments [Abstract]

Marketable Securities and Fair Value Measurements

The following tables present marketable securities by contractual maturity and security type:


As of June 30, 2022 (in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Due within one year:
Commercial paper	$	115,092	$	—	$	(405)	$	114,687
Corporate debt securities	111,796		3		(686)		111,113
Certificates of deposit	33,357		—		(117)		33,240
U.S. government securities	15,194		—		(84)		15,110
Due after one year through five years:
Corporate debt securities	7,464		—		(94)		7,370
U.S. government securities	1,898		—		(61)		1,837
Total	$	284,801	$	3	$	(1,447)	$	283,357


As of December 31, 2021 (in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Due within one year:
Commercial paper	$	105,433	$	1	$	(44)	$	105,390
Corporate debt securities	61,721		—		(70)		61,651
Certificates of deposit	23,528		1		(7)		23,522
U.S. government securities	8,008		—		—		8,008
Due after one year through five years:
Corporate debt securities	37,003		—		(129)		36,874
U.S. government securities	5,094		—		(18)		5,076
Total	$	240,787	$	2	$	(268)	$	240,521

The following tables present information about the Company's financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:


As of June 30, 2022 (in thousands)	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	—	$	44,875	$	—	$	44,875
U.S. government securities	—		2,299		—		2,299
Commercial paper	—		31,952		—		31,952
Certificates of deposit	—		5,198		—		5,198
Marketable securities:
Commercial paper	—		114,687		—		114,687
Corporate debt securities	—		118,483		—		118,483
Certificates of deposit	—		33,240		—		33,240
U.S. government securities	—		16,947		—		16,947
Total	$	—	$	367,681	$	—	$	367,681


As of December 31, 2021 (in thousands)	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	—	$	47,800	$	—	$	47,800


Marketable securities:
U.S. government securities	—		13,084		—		13,084
Commercial paper	—		105,390		—		105,390
Corporate debt securities	—		98,525		—		98,525
Certificates of deposit	—		23,522		—		23,522
Total	$	—	$	288,321	$	—	$	288,321

The tables above exclude certificates of deposit totaling $3.1 million as of both June 30, 2022 and December 31, 2021 that the Company held to secure a letter of credit associated with its leases and to secure a credit card account. The certificates of deposit are measured at carrying value in the consolidated balance sheets in long-term investments—restricted and approximate fair value. For additional information on the letter of credit associated with the Company's leases, please read Note 7, Leases, to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.

The fair value of Level 2 instruments classified as cash equivalents and marketable securities were determined through third-party pricing services. The pricing services use many observable market inputs to determine value, including reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates, and other industry and economic events. The Company performs validation procedures to ensure the reasonableness of this data. The Company performs its own review of prices received from the independent pricing services by comparing these prices to other sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by the pricing services as of June 30, 2022 and December 31, 2021

Inventory

6 Months Ended

Jun. 30, 2022

Inventory Disclosure [Abstract]

Inventory

Capitalized inventory consisted of the following:


(in thousands)	As of June 30, 2022		As of December 31, 2021
Raw materials	$	8,705	$	4,721
Work in process	10,908		7,925
Finished goods	1,276		1,479
Total inventory	$	20,889	$	14,125

Inventory written down as a result of excess, obsolescence, unmarketability, or other reasons is charged to cost of sales. For the three and six months ended June 30, 2022, there was $0.4 million in inventory written down and charged to cost of sales. There were no inventory amounts and less than $0.1 million in inventory written down and charged to cost of sales during the three and six months ended June 30, 2021, respectively.

Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2022

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consisted of the following:


(in thousands)	As of June 30, 2022		As of December 31, 2021
External research and development expenses	$	26,868	$	32,619
Restructuring reserve	2,018		20,790
Payroll and related expenses	9,293		11,945
Revenue-related reserves	11,542		8,722
Professional fees	3,840		5,626
Other	1,653		1,071
Total accrued expenses and other current liabilities	$	55,214	$	80,773

Stock-Based Awards

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

Stock-Based Awards

2017 Equity Incentive Plan

The Company grants stock-based awards under its 2017 Stock Option and Incentive Plan (the 2017 Plan) and is authorized to issue common stock under its 2017 Employee Stock Purchase Plan (ESPP). The Company also has outstanding stock options under its 2015 Equity Incentive Plan but is no longer granting awards under this plan. As of June 30, 2022, 1,437,072 shares of common stock were available for issuance under the 2017 Plan. As of June 30, 2022, 1,982,922 shares of common stock were available for issuance to participating employees under the ESPP.

2022 Inducement Plan

In January 2022, the Company adopted an inducement plan (the “Inducement Plan”) pursuant to which the Company reserved 800,000 shares of common stock to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market, Inc. The Inducement Plan provides for the grant of equity-based awards in the form of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, unrestricted stock awards, and dividend equivalent rights. The Inducement Plan was adopted by the Company without stockholder approval pursuant to Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market, Inc. As of June 30, 2022, there have been no grants made pursuant to the Inducement Plan.

Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2022		2021		2022		2021
Research and development	$	5,406	$	5,594	$	11,690	$	10,553
Selling, general, and administrative	7,582		6,777		15,566		12,937
Total stock-based compensation	$	12,988	$	12,371	$	27,256	$	23,490

As of June 30, 2022, total unrecognized compensation cost related to the unvested share-based awards was $84.6 million, which is expected to be recognized over a weighted average of 2.2 years.

Restructuring and Related Activities

6 Months Ended

Jun. 30, 2022

Restructuring and Related Activities [Abstract]

In-License Agreement

In November 2021, the Company announced a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research, and extend its cash runway. The corporate restructuring included a workforce reduction of approximately 35%, or approximately 140 positions, as well as discontinuation costs such as contract termination fees and non-cancellable commitments related to the rebastinib and ripretinib programs. These amounts will be substantially incurred and paid by the end of 2022.

The Company recognized a one-time charge in the fourth quarter of 2021 of approximately $26.2 million. This charge included approximately $9.8 million of employee-related termination costs and approximately $16.4 million of discontinuation costs such as contract termination fees and non-cancellable commitments related to the rebastinib and ripretinib programs. The restructuring reserve was included in accrued expenses and other in the Company’s consolidated balance sheets.

The following table summarizes the charges and spending related to the Company’s restructuring efforts during the six months ended June 30, 2022:


(in thousands)	Workforce Reduction		Pipeline Programs		Total
Restructuring reserve as of December 31, 2021	$	7,383	$	13,408	$	20,791
Payments	(6,772)		(12,001)		(18,773)
Restructuring reserve as of June 30, 2022	$	611	$	1,407	$	2,018

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments Associated with Commercial Supply Agreements The Company has entered into commercial supply agreements related to the supply of QINLOCK that require the Company to make binding forecasts for a certain amount of purchases. The related cancellation clauses would as a general matter require the Company to pay the full amount of these binding forecasts. As of June 30, 2022, the Company's contractual commitments for its commercial supply agreements were $12.5 million, of which $12.1 million are expected to be paid within one year. Legal Proceedings The Company is not currently a party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as they are incurred. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2022 or December 31, 2021.

Nature of the Business and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has incurred recurring losses including net losses of $90.0 million and $300.0 million for the six months ended June 30, 2022 and the year ended December 31, 2021, respectively. As of June 30, 2022, the Company had an accumulated deficit of $1.1 billion. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents, and marketable securities of $393.1 million as of June 30, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of these consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to fund its operations. The Company will need to obtain substantial additional funding in connection with continuing operations. If the Company is unable to raise capital when needed, or on attractive terms, it could be forced to delay, reduce, or eliminate its research or drug development programs or certain commercialization efforts. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. These consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). The consolidated balance sheet as of December 31, 2021 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited consolidated financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company's audited financial statements and the notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K (Form 10-K) on file with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company's consolidated financial position as of June 30, 2022 and consolidated results of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021 and consolidated cash flows for the six months ended June 30, 2022 and 2021 have been made. The consolidated results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, product revenue reserves, the accrual for research and development expenses, and the valuation of stock-based option awards. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Income Taxes Effective for tax years beginning on or after January 1, 2022, research and experimental expenditures under Internal Revenue Code Section 174 must be capitalized over five years when performed in the U.S. and 15 years for research and experimental expenditures performed outside of the U.S. The modification is an accounting method change that will require the filing of Form 3115 with the Company's 2022 tax return. As of June 30, 2022, the Company has performed an assessment of the impact of this legislation enactment and determined that it will not result in income tax due to enough net operating losses available that are not subject to an 80% limitation. The Company maintains its full valuation allowance. Leases - Sublease All of the Company's leases are operating leases. The Company determines the classification of a sublease at inception. If the sublease is determined to be an operating lease, the Company will recognize sublease income on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. If the sublease is determined to be a sales-type lease or direct financing lease, the Company will derecognize the right-of-use asset from the Company's original lease and record a net investment in the sublease and evaluate for impairment. The Company will account for the lease liability of the original lease based on the accounting for a lease liability in a finance lease. In May 2022, the Company entered into a sublease agreement to sublease 44,343 square feet of space at 200 Smith Street, Waltham, MA, for a term of three years for $8.9 million over the term of the sublease. The Company determined the sublease to be an operating lease. Therefore the Company will recognize sublease income on a straight-line basis over the lease term in its consolidated statement of operations and comprehensive income. The Company will continue to account for the right-of-use asset and related liability of the original lease as it did prior to the commencement of the sublease. During the three and six months ended June 30, 2022, the Company recognized $0.3 million of sublease income relating to lease payments within selling, general, and administrative expenses in the consolidated statement of operations and comprehensive loss.
Net Loss per Share	Net Loss per Share Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding for the period, including the pre-funded warrants given their nominal exercise price. Diluted net income (loss) per share is computed by dividing the diluted net income (loss) by the weighted average number of common shares, including the pre-funded warrants and potential dilutive common shares assuming the dilutive effect as determined using the treasury stock method.

Nature of the Business and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Potential Dilutive Securities


	As of June 30,
	2022	2021
Options to purchase common stock	8,205,617	6,798,894
Unvested restricted common stock units	1,942,621	814,277
Unvested employee stock purchase plan shares	53,429	34,183
Total	10,201,667	7,647,354

Revenues (Tables)

6 Months Ended

Jun. 30, 2022

Disaggregation of Product Revenues, Net [Line Items]

Analysis Of Amount Of And Change In Product Revenue Reserves.

Activity in each of the product revenue allowance and reserve categories is summarized as follows:


(in thousands)	Trade discounts and allowances		Chargebacks and administrative fees		Government rebates and other incentives		Returns		Total
Balance as of December 31, 2021	$	267	$	494	$	7,863	$	817	$	9,441
Provision related to sales in the current year	1,734		3,686		5,536		1,211		12,167
Adjustments related to prior period sales	—		(16)		(164)		(239)		(419)
Credits and payments made during the period	(1,566)		(3,543)		(2,416)		(1,126)		(8,651)
Balance as of June 30, 2022	$	435	$	621	$	10,819	$	663	$	12,538

Summary Of Total Product Revenue Reserves Included In The Consolidated Balance Sheets

The total reserves described above are summarized as components of the Company's consolidated balance sheets as follows:


(in thousands)	As of June 30, 2022		As of December 31, 2021
Reduction of accounts receivable, net	$	996	$	719
Component of accrued expenses and other current liabilities	11,542		8,722
Total revenue-related reserves	$	12,538	$	9,441

Product revenues, net

Disaggregation of Product Revenues, Net [Line Items]

Disaggregation of Product Revenue

Net product revenues by geography consisted of the following:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2022		2021		2022		2021
U.S.	$	23,733	$	20,732	$	47,142	$	40,019
Rest of world	7,764		1,316		13,164		1,991
Total product revenues, net	$	31,497	$	22,048	$	60,306	$	42,010

Marketable Securities and Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2022

Investments, All Other Investments [Abstract]

Schedule of Marketable Securities

The following tables present marketable securities by contractual maturity and security type:


As of June 30, 2022 (in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Due within one year:
Commercial paper	$	115,092	$	—	$	(405)	$	114,687
Corporate debt securities	111,796		3		(686)		111,113
Certificates of deposit	33,357		—		(117)		33,240
U.S. government securities	15,194		—		(84)		15,110
Due after one year through five years:
Corporate debt securities	7,464		—		(94)		7,370
U.S. government securities	1,898		—		(61)		1,837
Total	$	284,801	$	3	$	(1,447)	$	283,357


As of December 31, 2021 (in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Due within one year:
Commercial paper	$	105,433	$	1	$	(44)	$	105,390
Corporate debt securities	61,721		—		(70)		61,651
Certificates of deposit	23,528		1		(7)		23,522
U.S. government securities	8,008		—		—		8,008
Due after one year through five years:
Corporate debt securities	37,003		—		(129)		36,874
U.S. government securities	5,094		—		(18)		5,076
Total	$	240,787	$	2	$	(268)	$	240,521

Schedule of Financial Assets Measured at Fair Value on a Recurring Basis


As of June 30, 2022 (in thousands)	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	—	$	44,875	$	—	$	44,875
U.S. government securities	—		2,299		—		2,299
Commercial paper	—		31,952		—		31,952
Certificates of deposit	—		5,198		—		5,198
Marketable securities:
Commercial paper	—		114,687		—		114,687
Corporate debt securities	—		118,483		—		118,483
Certificates of deposit	—		33,240		—		33,240
U.S. government securities	—		16,947		—		16,947
Total	$	—	$	367,681	$	—	$	367,681


As of December 31, 2021 (in thousands)	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	—	$	47,800	$	—	$	47,800


Marketable securities:
U.S. government securities	—		13,084		—		13,084
Commercial paper	—		105,390		—		105,390
Corporate debt securities	—		98,525		—		98,525
Certificates of deposit	—		23,522		—		23,522
Total	$	—	$	288,321	$	—	$	288,321

Inventory (Tables)

6 Months Ended

Jun. 30, 2022

Inventory Disclosure [Abstract]

Schedule of Inventory

Capitalized inventory consisted of the following:


(in thousands)	As of June 30, 2022		As of December 31, 2021
Raw materials	$	8,705	$	4,721
Work in process	10,908		7,925
Finished goods	1,276		1,479
Total inventory	$	20,889	$	14,125

Accrued Expenses and Other Current Liabilities (Tables)

6 Months Ended

Jun. 30, 2022

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:


(in thousands)	As of June 30, 2022		As of December 31, 2021
External research and development expenses	$	26,868	$	32,619
Restructuring reserve	2,018		20,790
Payroll and related expenses	9,293		11,945
Revenue-related reserves	11,542		8,722
Professional fees	3,840		5,626
Other	1,653		1,071
Total accrued expenses and other current liabilities	$	55,214	$	80,773

Stock-Based Awards (Tables)

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

Classification of Stock-Based Compensation Expense

Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2022		2021		2022		2021
Research and development	$	5,406	$	5,594	$	11,690	$	10,553
Selling, general, and administrative	7,582		6,777		15,566		12,937
Total stock-based compensation	$	12,988	$	12,371	$	27,256	$	23,490

Nature of the Business and Summary of Significant Accounting Policies - Summary of Potential Dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share (in shares)	10,201,667	7,647,354
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share (in shares)	8,205,617	6,798,894
Unvested restricted common stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share (in shares)	1,942,621	814,277
Unvested employee stock purchase plan shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share (in shares)	53,429	34,183

Nature of the Business and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended
	Apr. 29, 2022	Aug. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	May 31, 2022	Apr. 26, 2022	Dec. 31, 2021
Nature Of Business And Basis Of Presentation [Line Items]
Issuance of common stock, net of underwriting discounts, commissions and offering costs	$ 163,400,000		$ 163,353,000		$ 163,353,000	$ 8,548,000
Net loss			(43,061,000)	$ (70,433,000)	(89,953,000)	(131,731,000)	$ (300,000,000)
Accumulated deficit			(1,144,385,000)		(1,144,385,000)					$ (1,054,432,000)
Investments and cash			$ 393,100,000		393,100,000
Proceeds from Warrant Exercises					$ 3,000	$ 0
Class of Warrant or Right, Outstanding			9,431,445		9,431,445
Lessor, Operating Sublease, Term			3 years		3 years
Lessor, Operating Lease, Payments to be Received								$ 8,900,000
Sublease Income			$ 300,000		$ 300,000
Common Stock
Nature Of Business And Basis Of Presentation [Line Items]
Number of shares issued and sold (in shares)	7,501,239		7,501,239		7,501,239	172,094
Offering price of common stock and warrants issued (in dollars per share)									$ 10.00
Issuance of common stock, net of underwriting discounts, commissions and offering costs			$ 75,000		$ 75,000	$ 2,000
Warrant
Nature Of Business And Basis Of Presentation [Line Items]
Number of shares issued and sold (in shares)	9,748,761		317,316		317,316
Offering price of common stock and warrants issued (in dollars per share)									9.99
Exercise price of warrants issued									$ 0.01
Issuance of common stock, net of underwriting discounts, commissions and offering costs			$ 3,000		$ 3,000
Proceeds from Warrant Exercises					$ 100,000
Open Market Sale Agreement
Nature Of Business And Basis Of Presentation [Line Items]
Offering proceeds		$ 200,000,000
Open Market Sale Agreement \| Common Stock
Nature Of Business And Basis Of Presentation [Line Items]
Number of shares issued and sold (in shares)						172,094
Issuance of common stock, net of underwriting discounts, commissions and offering costs						$ 8,500,000

Revenues - Net Product Revenues by Geography (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Product Revenues, Net [Line Items]
Total revenues	$ 32,494	$ 23,573	$ 61,717	$ 48,729
Product revenues, net
Disaggregation of Product Revenues, Net [Line Items]
Total revenues	31,497	22,048	60,306	42,010
Product revenues, net \| U.S.
Disaggregation of Product Revenues, Net [Line Items]
Total revenues	23,733	20,732	47,142	40,019
Product revenues, net \| Rest of world
Disaggregation of Product Revenues, Net [Line Items]
Total revenues	$ 7,764	$ 1,316	$ 13,164	$ 1,991

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenues - Product Revenue Allowance and Reserve Categories (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	$ 9,441
Provision related to sales in the current year	12,167
Adjustments related to prior period sales	(419)
Credits and payments made during the period	(8,651)
Ending balance	12,538
Trade discounts and allowances
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	267
Provision related to sales in the current year	1,734
Adjustments related to prior period sales	0
Credits and payments made during the period	(1,566)
Ending balance	435
Chargebacks and administrative fees
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	494
Provision related to sales in the current year	3,686
Adjustments related to prior period sales	(16)
Credits and payments made during the period	(3,543)
Ending balance	621
Government rebates and other incentives
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	7,863
Provision related to sales in the current year	5,536
Adjustments related to prior period sales	(164)
Credits and payments made during the period	(2,416)
Ending balance	10,819
Returns
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	817
Provision related to sales in the current year	1,211
Adjustments related to prior period sales	(239)
Credits and payments made during the period	(1,126)
Ending balance	$ 663

Revenues - Total Reserves Summarized (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue-related reserves	$ 12,538	$ 9,441
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Revenue-related reserves	12,538	9,441
Accounts Receivable
Revenue from Contract with Customer [Abstract]
Revenue-related reserves	996	719
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Revenue-related reserves	996	719
Accrued Expenses And Other Current Liabilities
Revenue from Contract with Customer [Abstract]
Revenue-related reserves	11,542	8,722
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Revenue-related reserves	$ 11,542	$ 8,722

Revenues - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2019	Jun. 30, 2022	Jun. 30, 2021
Revenue from External Customer [Line Items]
Revenues		$ 32,494		$ 23,573		$ 61,717	$ 48,729
Zai License Agreement \| Development Milestone \| Maximum
Revenue from External Customer [Line Items]
License agreement milestone						38,000
Zai License Agreement \| Development And Commercial Milestone \| Maximum
Revenue from External Customer [Line Items]
License agreement milestone						173,000
Zai License Agreement \| Commercial Milestone \| Maximum
Revenue from External Customer [Line Items]
License agreement milestone	$ 135,000
Product revenues, net
Revenue from External Customer [Line Items]
Revenues		31,497		22,048		60,306	42,010
Collaboration revenues
Revenue from External Customer [Line Items]
Revenues		$ 997		1,525		$ 1,411	$ 6,719
Collaboration revenues \| Zai License Agreement \| Upfront Payment
Revenue from External Customer [Line Items]
Revenues					$ 20,000
Collaboration revenues \| Zai License Agreement \| Development Milestone
Revenue from External Customer [Line Items]
Revenues			$ 12,000	$ 5,000

Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Amortized Cost		$ 284,801	$ 240,787
Gross Unrealized Gains	$ 2	3
Gross Unrealized Losses	(268)	(1,447)
Estimated Fair Value		283,357	240,521
Commercial paper
Marketable Securities [Line Items]
Amortized Cost, due within one year		115,092	105,433
Gross Unrealized Gains, due within one year	1	0
Gross Unrealized Losses, due within one year	(44)	(405)
Estimated Fair Value, due within one year		114,687	105,390
Estimated Fair Value		114,687	105,390
Corporate debt securities
Marketable Securities [Line Items]
Amortized Cost, due within one year		111,796	61,721
Amortized Cost, due after one year through five years		7,464	37,003
Gross Unrealized Gains, due within one year	0	3
Gross Unrealized Gains, due after one year through five years	0	0
Gross Unrealized Losses, due within one year	(70)	(686)
Gross Unrealized Losses, due after one year through five years	(129)	(94)
Estimated Fair Value, due within one year		111,113	61,651
Estimated Fair Value, due after one year through five years		7,370	36,874
Estimated Fair Value		118,483	98,525
Certificates of deposit
Marketable Securities [Line Items]
Amortized Cost, due within one year		33,357	23,528
Gross Unrealized Gains, due within one year	1	0
Gross Unrealized Losses, due within one year	(7)	(117)
Estimated Fair Value, due within one year		33,240	23,522
Estimated Fair Value		33,240	23,522
U.S. government securities
Marketable Securities [Line Items]
Amortized Cost, due within one year		15,194	8,008
Amortized Cost, due after one year through five years		1,898	5,094
Gross Unrealized Gains, due within one year	0	0
Gross Unrealized Gains, due after one year through five years	0	0
Gross Unrealized Losses, due within one year	0	(84)
Gross Unrealized Losses, due after one year through five years	$ (18)	(61)
Estimated Fair Value, due within one year		15,110	8,008
Estimated Fair Value, due after one year through five years		1,837	5,076
Estimated Fair Value		$ 16,947	$ 13,084

Marketable Securities and Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Marketable securities:
Total Marketable Securities	$ 283,357	$ 240,521
Total	367,681	288,321
U.S. government securities
Marketable securities:
Total Marketable Securities	16,947	13,084
Commercial paper
Marketable securities:
Total Marketable Securities	114,687	105,390
Corporate debt securities
Marketable securities:
Total Marketable Securities	118,483	98,525
Certificates of deposit
Marketable securities:
Total Marketable Securities	33,240	23,522
Money market funds
Cash equivalents:
Total Cash equivalents	44,875	47,800
U.S. government securities
Cash equivalents:
Total Cash equivalents	2,299
Commercial paper
Cash equivalents:
Total Cash equivalents	31,952
Certificates of deposit
Cash equivalents:
Total Cash equivalents	5,198
Level 1
Marketable securities:
Total	0	0
Level 1 \| U.S. government securities
Marketable securities:
Total Marketable Securities	0	0
Level 1 \| Commercial paper
Marketable securities:
Total Marketable Securities	0	0
Level 1 \| Corporate debt securities
Marketable securities:
Total Marketable Securities	0	0
Level 1 \| Certificates of deposit
Marketable securities:
Total Marketable Securities	0	0
Level 1 \| Money market funds
Cash equivalents:
Total Cash equivalents	0	0
Level 1 \| U.S. government securities
Cash equivalents:
Total Cash equivalents	0
Level 1 \| Commercial paper
Cash equivalents:
Total Cash equivalents	0
Level 1 \| Certificates of deposit
Cash equivalents:
Total Cash equivalents	0
Level 2
Marketable securities:
Total	367,681	288,321
Level 2 \| U.S. government securities
Marketable securities:
Total Marketable Securities	16,947	13,084
Level 2 \| Commercial paper
Marketable securities:
Total Marketable Securities	114,687	105,390
Level 2 \| Corporate debt securities
Marketable securities:
Total Marketable Securities	118,483	98,525
Level 2 \| Certificates of deposit
Marketable securities:
Total Marketable Securities	33,240	23,522
Level 2 \| Money market funds
Cash equivalents:
Total Cash equivalents	44,875	47,800
Level 2 \| U.S. government securities
Cash equivalents:
Total Cash equivalents	2,299
Level 2 \| Commercial paper
Cash equivalents:
Total Cash equivalents	31,952
Level 2 \| Certificates of deposit
Cash equivalents:
Total Cash equivalents	5,198
Level 3
Marketable securities:
Total	0	0
Level 3 \| U.S. government securities
Marketable securities:
Total Marketable Securities	0	0
Level 3 \| Commercial paper
Marketable securities:
Total Marketable Securities	0	0
Level 3 \| Corporate debt securities
Marketable securities:
Total Marketable Securities	0	0
Level 3 \| Certificates of deposit
Marketable securities:
Total Marketable Securities	0	0
Level 3 \| Money market funds
Cash equivalents:
Total Cash equivalents	0	$ 0
Level 3 \| U.S. government securities
Cash equivalents:
Total Cash equivalents	0
Level 3 \| Commercial paper
Cash equivalents:
Total Cash equivalents	0
Level 3 \| Certificates of deposit
Cash equivalents:
Total Cash equivalents	$ 0

Marketable Securities and Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Certificates of deposit \| Letter of Credit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certificate of deposit held to secure letter of credit associated with lease and credit card	$ 3.1	$ 3.1

Inventory (Details) - USD ($)	3 Months Ended		6 Months Ended
Inventory (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 8,705,000		$ 8,705,000		$ 4,721,000
Work in process	10,908,000		10,908,000		7,925,000
Total inventory	1,276,000		1,276,000		1,479,000
Inventory	20,889,000		20,889,000		$ 14,125,000
Inventory written down	$ 400,000	$ 0	$ 400,000	$ 100,000

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule of Accrued Expenses and Other Current Liabilities
External research and development expenses	$ 26,868	$ 32,619
Restructuring reserve	2,018	20,790
Payroll and related expenses	9,293	11,945
Revenue-related reserves	12,538	9,441
Professional fees	3,840	5,626
Other	1,653	1,071
Total accrued expenses and other current liabilities	55,214	80,773
Accrued Expenses And Other Current Liabilities
Schedule of Accrued Expenses and Other Current Liabilities
Revenue-related reserves	$ 11,542	$ 8,722

Stock-Based Awards - Classification of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 12,988	$ 12,371	$ 27,256	$ 23,490
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	5,406	5,594	11,690	10,553
Selling, general, and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 7,582	$ 6,777	$ 15,566	$ 12,937

Stock-Based Awards - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 01, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested share-based awards	$ 84,600		$ 84,600
Unrecognized compensation cost related to unvested share-based awards, period for recognition			2 years 2 months 12 days
Share-based compensation expense	$ 12,988	$ 12,371	$ 27,256	$ 23,490
2017 Stock Option and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance (in shares)	1,437,072		1,437,072
Employee Stock Purchase Plan (ESPP)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance (in shares)	1,982,922		1,982,922
Inducement Plan \| Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance (in shares)					800,000

Restructuring and Related Activities (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 2,018		$ 20,791
Payments for Restructuring	(18,773)
Restructuring Charges		$ 26,200
Workforce Reduction
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	611		7,383
Payments for Restructuring	(6,772)
Restructuring Charges		9,800
Pipeline programs
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,407		$ 13,408
Payments for Restructuring	$ (12,001)
Restructuring Charges		$ 16,400

Commitments and Contingencies - Additional Information (Details) - Supply Commitment $ in Millions	Jun. 30, 2022 USD ($)
Other Commitments [Line Items]
Supply commitment amount	$ 12.5
Supply commitment, remaining minimum amount committed, to be paid, year one	$ 12.1